Leela Raju, MD
Ophthalmology · New York, NYNPI 1972705069
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $12,475 of the $19,271 with a category attached, or 64.7%. 23 manufacturers reported payments, led by Carl Zeiss Meditec, Inc. at 32.4% of the total. Reporting peaked in 2019 at $6,369 and has fallen 64.0% since, to $2,291 in 2025. Among ophthalmology clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 99 payments — averaging $194.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Carl Zeiss Meditec, Inc.$6K
- Johnson & Johnson Surgical Vision, Inc.$3K
- AbbVie$2K
- PTC Therapeutics, Inc.$2K
- Alcon$2K
- NEW World Medical,inc.$813
- plus $3K from 17 others
What the payments were for
- Consulting fees$12,47565%
- Speaking & faculty fees$7004%
- Travel & lodging$4162%
- Food & beverage$5,68029%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Carl Zeiss Meditec, Inc. | 10 | $6,245 |
| Johnson & Johnson Surgical Vision, Inc. | 4 | $2,931 |
| AbbVie(2 entities) | 6 | $2,054 |
| PTC Therapeutics, Inc. | 4 | $2,025 |
| Alcon | 22 | $2,019 |
| NEW World Medical,inc. | 2 | $813 |
| Lensar, Inc. | 1 | $700 |
| Tarsus Pharmaceuticals, Inc. | 4 | $387 |
| Novartis | 6 | $386 |
| Dompe US, Inc. | 7 | $328 |
| Bausch & Lomb Americas Inc. | 5 | $315 |
| Ocular Therapeutix, Inc. | 7 | $226 |
| Carl Zeiss Meditec USA, Inc. | 1 | $210 |
| Glaukos Corporation | 2 | $210 |
| ANI Pharmaceuticals, Inc. | 4 | $88 |
| Carl Zeiss Meditec Cataract Technology Inc. | 1 | $88 |
| Biotissue Holdings Inc. | 4 | $65 |
| Oyster Point Pharma, Inc. | 3 | $51 |
| Sun Pharmaceutical Industries Inc. | 2 | $49 |
| Sight Sciences, Inc. | 1 | $25 |
| Thea Pharma Inc. | 1 | $24 |
| Rayner Intraocular Lenses Limited | 1 | $18 |
| Endo Pharmaceuticals Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VisuMax$4,900
- QUATERA 700$4,013
- CIRRUS HD-OCT$3,850
- CLARUS$2,800
- VERACITY SURGICAL$1,932
- IOLMaster 700$1,563
- Tecnis Symfony IOL$1,500
- Tecnis Simplicity$1,300
- IFS ADVANCED FEMTOSEC LASER$1,300
- INTRALASE FS FEMTOSEC LASER$1,300
- MEL 90$1,050
- CALLISTO eye$1,050
- LUMERA$882
- LENSAR LASER SYSTEM$700
- Clareon$476
- AcrySof IQ VIVITY$149
- NGENUITY$147
- Centurion$144
- ACTIVEFOCUS$144
- ARGOS$142
How this compares
$19,271 in reported general payments places this provider in the 90th percentile of 1,587 ophthalmology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 75 | $54,081 |
| LumiganBimatoprost | 56 | $21,442 |
| XiidraLifitegrast | 12 | $12,290 |
| Travoprost | 48 | $10,881 |
| CombiganBrimonidine Tartrate/Timolol | 11 | $5,930 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 24 | $5,928 |
| Cyclosporine | 13 | $4,938 |
| Brimonidine Tartrate | 44 | $3,627 |
| Latanoprost | 324 | $3,385 |
| Prednisolone Acetate | 42 | $1,504 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 87 | $1,468 |
| Timolol Maleate | 69 | $809 |
| ValacyclovirValacyclovir Hcl | 20 | $701 |
| Azelastine Hcl | 14 | $356 |
| Ketorolac Tromethamine | 19 | $303 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $2,054 | $81,454142 claims |
| Bausch & Lomb Americas Inc.Xiidra | $315 | $12,29012 claims |
| AlconSimbrinza | $2,019 | $5,92824 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,587 ophthalmology providers in New York.
Other ophthalmology in New York
- Nathan RadcliffeNew York$2.1M
- Richard SpaideNew York$1.7M
- Joshua YoungNew York$814K
- Joseph PanarelliNew York$541K
- Eric RosenbergNew York$434K
- Michael CooneyNew York$398K
- David GuyerNew York$322K
- Ashley BrissetteNew York$315K
- Jason SlakterNew York$272K
- David ChuNew York$234K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.